급성 호흡기질환 진단 시장 규모, 점유율, 동향 분석 보고서 : 검사별, 병원체별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Acute Respiratory Disease Diagnostics Market Summary

The global acute respiratory disease diagnostics market size was estimated at USD 5.49 billion in 2024 and is projected to reach USD 10.71 billion by 2033, growing at a CAGR of 7.01% from 2025 to 2033. Some of the major factors driving the market are rising disease burden of respiratory conditions, advancements in diagnostic technologies, and increasing demand for early detection & decentralized testing.

According to the Institute for Health Metrics and Evaluation (IHME) in April 2023, chronic respiratory diseases (CRDs) are the third leading cause of death globally. Furthermore, the market growth is driven by the ageing demographic shift, increased healthcare infrastructure & investment in developing markets, government initiatives, public health programs & funding. The rise in the proportion of older people globally has led to an increase in cases of respiratory disorders, as older age is often associated with decreased lung capacity and decreased immune functioning. This demographic shift introduces significant risk for the development of chronic and acute infections with co-morbidities, including pneumonia, chronic obstructive pulmonary disease (COPD), and influenza. As a result, there is an increasing demand for rapid and accurate diagnostic tools for early detection, timely intervention, and improved clinical outcomes among the aging demographic.

Simultaneously, the healthcare infrastructure in emerging economies is rapidly expanding, providing a solid base for the adoption of new diagnostic techniques. Countries in the Asia-Pacific, Latin America, and Middle East regions are seeing significant investments in the modernization of healthcare, laboratory automation, and the development of innovative devices. Governments and private healthcare providers are collaborating to enhance diagnostic capacity through public-private partnerships, the establishment of specialized respiratory testing centers, and the implementation of point-of-care testing. These efforts will lead to increased access to diagnostic services, shorter turnaround times, and enhanced disease management in both urban and rural areas.

In addition, government programs and international public health initiatives play a crucial role in supporting the global diagnostic ecosystem. Existing efforts by the WHO, the Global Fund, and the Ministries of Health of various countries to enhance surveillance of respiratory diseases, fund research, and provide equitable access to critical diagnostic supplies indicate that the global diagnostic community is working collaboratively to strengthen diagnostic capabilities worldwide and improve public health. Changes in reimbursement environments, public awareness campaigns, global strategic funding for innovations, and collaborative research efforts are reshaping global adherence to molecular and digital diagnostics. Overall, these aims aim to provide an ecosystem and ultimately improve public health by reducing the burden of acute respiratory disease through early, accurate, and accessible diagnostics.

Global Acute Respiratory Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global acute respiratory disease diagnostics market based on test, pathogen, end-use, and region:

• Test Outlook (Revenue, USD Million, 2021 - 2033)
• Molecular Diagnostics
  • PCR
  • INAAT
• Antigen-based Rapid Tests
• Serological Tests (IgM/IgG)
• Syndromic Respiratory Panels
• Other Emerging Technologies (CRISPR-based, Nanopore Sequencing, AI-driven Imaging)
• Pathogen Outlook (Revenue, USD Million, 2021 - 2033)
• Viral Infections
  • Influenza A & B
  • Respiratory Syncytial Virus (RSV)
  • SARS-CoV-2
  • Others
• Bacterial Infections
  • Streptococcus pneumoniae
  • Haemophilus influenzae
  • Mycoplasma pneumoniae
  • Bordetella pertussis
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic and Reference Labs
• Home Testing
• Others (Public health, surveillance labs)
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Acute Respiratory Disease Diagnostics Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Test Method
    • 1.1.1.2. Pathogen Segment
    • 1.1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Acute Respiratory Disease Diagnostics Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Test Snapshot
• 2.3. Pathogen Snapshot
• 2.4. End Use Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Acute Respiratory Disease Diagnostics Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising disease burden of respiratory conditions
  • 3.4.2. Advancements in diagnostic technologies
  • 3.4.3. Increasing demand for early detection and decentralised testing
• 3.5. Market Restraint Analysis
  • 3.5.1. High cost of advanced diagnostics
  • 3.5.2. Limited awareness and under-screening
  • 3.5.3. Infrastructure & skilled workforce constraints
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Acute Respiratory Disease Diagnostics Market: Test Estimates & Trend Analysis

• 4.1. Acute Respiratory Disease Diagnostics Market: Test Movement Analysis
• 4.2. Molecular Diagnostics
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.2. PCR
    • 4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.3. INAAT
    • 4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.3. Antigen-based Rapid Tests
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Serological Tests (IgM/IgG)
  • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Syndromic Respiratory Panels
  • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Other Emerging Technologies (CRISPR-based, Nanopore Sequencing, AI-driven Imaging)
  • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Acute Respiratory Disease Diagnostics Market: Pathogen Estimates & Trend Analysis

• 5.1. Acute Respiratory Disease Diagnostics Market: Pathogen Movement Analysis
• 5.2. Viral Infections
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.2. Influenza A & B
    • 5.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.3. Respiratory Syncytial Virus (RSV)
    • 5.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.4. SARS-CoV-2
    • 5.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.2.5. Others
    • 5.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Bacterial Infections
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.2. Streptococcus pneumoniae
    • 5.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.3. Haemophilus influenzae
    • 5.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.4. Mycoplasma pneumoniae
    • 5.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.5. Bordetella pertussis
    • 5.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Others
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Acute Respiratory Disease Diagnostics Market: End Use Estimates & Trend Analysis

• 6.1. Acute Respiratory Disease Diagnostics Market: End Use Movement Analysis
• 6.2. Hospitals & Clinics
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Diagnostic and Reference Labs
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Home Testing
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Others (Public health, surveillance labs)
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Acute Respiratory Disease Diagnostics Market: Regional Business Analysis

• 7.1. Regional Market Snapshot
• 7.2. North America
  • 7.2.1. North America Acute Respiratory Disease Diagnostics Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.2.2.2. Key Country Dynamics
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Reimbursement Scenario
    • 7.2.2.5. Competitive Scenario
  • 7.2.3. Canada
    • 7.2.3.1. Canada Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.2.3.2. Key Country Dynamics
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Reimbursement Scenario
    • 7.2.3.5. Competitive Scenario
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.2.4.2. Key Country Dynamics
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Reimbursement Scenario
    • 7.2.4.5. Competitive Scenario
• 7.3. Europe
  • 7.3.1. Europe Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.2.2. Key Country Dynamics
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Reimbursement Scenario
    • 7.3.2.5. Competitive Scenario
  • 7.3.3. Germany
    • 7.3.3.1. Germany Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.3.2. Key Country Dynamics
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Reimbursement Scenario
    • 7.3.3.5. Competitive Scenario
  • 7.3.4. Spain
    • 7.3.4.1. Spain Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.4.2. Key Country Dynamics
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Reimbursement Scenario
    • 7.3.4.5. Competitive Scenario
  • 7.3.5. France
    • 7.3.5.1. France Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.5.2. Key Country Dynamics
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Reimbursement Scenario
    • 7.3.5.5. Competitive Scenario
  • 7.3.6. Italy
    • 7.3.6.1. Italy Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.6.2. Key Country Dynamics
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Reimbursement Scenario
    • 7.3.6.5. Competitive Scenario
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.7.2. Key Country Dynamics
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Reimbursement Scenario
    • 7.3.7.5. Competitive Scenario
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.8.2. Key Country Dynamics
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Reimbursement Scenario
    • 7.3.8.5. Competitive Scenario
  • 7.3.9. Norway
    • 7.3.9.1. Norway Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.9.2. Key Country Dynamics
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Reimbursement Scenario
    • 7.3.9.5. Competitive Scenario
• 7.4. Asia Pacific
  • 7.4.1. Asia-Pacific Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.2.2. Key Country Dynamics
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Scenario
    • 7.4.2.5. Competitive Scenario
  • 7.4.3. China
    • 7.4.3.1. China Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.3.2. Key Country Dynamics
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Scenario
    • 7.4.3.5. Competitive Scenario
  • 7.4.4. India
    • 7.4.4.1. India Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.4.2. Key Country Dynamics
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Scenario
    • 7.4.4.5. Competitive Scenario
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.5.2. Key Country Dynamics
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Reimbursement Scenario
    • 7.4.5.5. Competitive Scenario
  • 7.4.6. Thailand
    • 7.4.6.1. Thailand Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.6.2. Key Country Dynamics
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Reimbursement Scenario
    • 7.4.6.5. Competitive Scenario
  • 7.4.7. Australia
    • 7.4.7.1. Australia Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.7.2. Key Country Dynamics
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Reimbursement Scenario
    • 7.4.7.5. Competitive Scenario
• 7.5. Latin America
  • 7.5.1. Latin America Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.5.2.2. Key Country Dynamics
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. Competitive Scenario
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.5.3.2. Key Country Dynamics
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Competitive Scenario
• 7.6. MEA
  • 7.6.1. MEA Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.6.2.2. Key Country Dynamics
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. Competitive Scenario
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.6.3.2. Key Country Dynamics
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. Competitive Scenario
  • 7.6.4. UAE
    • 7.6.4.1. UAE Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.6.4.2. Key Country Dynamics
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. Competitive Scenario
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Acute Respiratory Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.6.5.2. Key Country Dynamics
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
  • 8.2.1. New Product Launch
  • 8.2.2. Partnerships
  • 8.2.3. Acquisition
  • 8.2.4. Collaboration
  • 8.2.5. Funding
• 8.3. Key Company Market Share Analysis, 2024
• 8.4. Company Heat Map Analysis
• 8.5. Company Profiles
  • 8.5.1. F. Hoffmann La-Roche
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Abbott Laboratories
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Quidel Corporation
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Becton, Dickinson and Company (BD)
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Thermo Fisher Scientific, Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Siemens Healthineers
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Bio-Rad Laboratories
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Luminex Corporation
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. BioMerieux
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Meridian Bioscience
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. Fujirebio Diagnostics
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives
  • 8.5.12. Cepheid
    • 8.5.12.1. Overview
    • 8.5.12.2. Financial Performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic Initiatives
  • 8.5.13. Lumos Diagnostics
    • 8.5.13.1. Overview
    • 8.5.13.2. Financial Performance
    • 8.5.13.3. Product Benchmarking
    • 8.5.13.4. Strategic Initiatives